Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celgene Corp (CELG)

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,982,504
  • Shares Outstanding, K 711,714
  • Annual Sales, $ 15,281 M
  • Annual Income, $ 4,046 M
  • 60-Month Beta 1.41
  • Price/Sales 5.10
  • Price/Cash Flow 12.35
  • Price/Book 6.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 2.88
  • Number of Estimates 2
  • High Estimate 3.04
  • Low Estimate 2.72
  • Prior Year 2.20
  • Growth Rate Est. (year over year) +30.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.11 +9.88%
on 10/14/19
110.47 -0.43%
on 11/12/19
+9.43 (+9.38%)
since 10/11/19
3-Month
92.70 +18.66%
on 08/15/19
110.47 -0.43%
on 11/12/19
+15.93 (+16.93%)
since 08/12/19
52-Week
58.59 +87.75%
on 12/26/18
110.47 -0.43%
on 11/12/19
+38.98 (+54.89%)
since 11/12/18

Most Recent Stories

More News
Celgene Corp Rises 9.25% on Heavy Volume: Watch For Potential Pullback

Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.40 to a high of $109.78. Yesterday, the shares gained 9.3%, which took the trading range above the 3-day high of...

CELG : 110.00 (+0.39%)
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets.

CELGZ : 0.48 (unch)
CELG : 110.00 (+0.39%)
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

ACAD : 46.33 (+2.41%)
CHRS : 18.43 (-1.97%)
CELG : 110.00 (+0.39%)
INCY : 86.14 (+1.51%)
Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases

The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells

EDIT : 22.32 (+9.47%)
CELG : 110.00 (+0.39%)
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued...

CELGZ : 0.48 (unch)
BMY : 58.39 (+0.41%)
CELG : 110.00 (+0.39%)
4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

BMY : 58.39 (+0.41%)
LLY : 113.17 (+0.33%)
ACAD : 46.33 (+2.41%)
CHRS : 18.43 (-1.97%)
CELG : 110.00 (+0.39%)
BIIB : 291.40 (-0.93%)
INCY : 86.14 (+1.51%)
ADPT : 28.35 (+0.11%)
ALEC : 16.31 (-2.22%)
NGM : 13.00 (+1.40%)
TAK : 19.62 (-0.56%)
Celgene (CELG) Hits 52-Week High, Can the Run Continue?

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CELG : 110.00 (+0.39%)
REGN : 348.41 (+1.20%)
ALXN : 109.44 (+0.39%)
GHDX : 63.44 (-0.69%)
Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug

Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.

BMY : 58.39 (+0.41%)
VRTX : 203.86 (+0.97%)
XLRN : 44.86 (+0.65%)
CELG : 110.00 (+0.39%)
FDA Approves REBLOZYL(R) (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

--Approval of REBLOZYL marks the first FDA-approved treatment for anemia in beta thalassemia

CELGZ : 0.48 (unch)
CELG : 110.00 (+0.39%)
XLRN : 44.86 (+0.65%)
Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales

Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.

LLY : 113.17 (+0.33%)
CELG : 110.00 (+0.39%)
CORT : 16.11 (+1.13%)
TRIL : 0.27 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade CELG with:

Business Summary

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID,...

See More

Key Turning Points

2nd Resistance Point 111.03
1st Resistance Point 110.51
Last Price 110.00
1st Support Level 109.44
2nd Support Level 108.89

See More

52-Week High 110.47
Last Price 110.00
Fibonacci 61.8% 90.65
Fibonacci 50% 84.53
Fibonacci 38.2% 78.41
52-Week Low 58.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar